The adipocyte cGMP-inhibited cyclic nucleotide phosphodiesterase (PDE3B) as a target for lipolytic and thermogenic agents for the treatment of obesity

Expert Opinion on Therapeutic Targets

Volumn 3, Issue 4, 1999, Pages 587-599

  Snyder, Peter B ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

cGMP inhibited phosphodiesterase; lipolysis; non insulin dependent diabetes mellitus; obesity; PDE3B; thermogenesis

Indexed keywords

EID: 80052015104     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.3.4.587     Document Type: Review

References (68)

1. KUCZMARSKI RJ, FLEGAL KM, CAMPBELL SM, JOHNSON CL: Increasing prevalence of overweight among US adults. J. Am. Med. Assoc. (1995) 272:205-211.
2. SEIDELL JC, RISSANEN AM: Time trends in the worldwide prevalence of obesity. In: Handbook of Obesity. Bray GA, Bouchard C, James WPT (Eds.) Marcel Dekker, Inc., New York, USA (1998):79-91.
3. BRAY GA: Pharmacological treatment of obesity. In: Handbook of Obesity. Bray GA, Bouchard C, James WPT (Eds.) Marcel Dekker, Inc., New York, USA (1998):953-975.
4. DAVIDSON MH, HAUPTMAN J, DIGIROLAMO M et al.: Weight control and risk factor reduction in obese subjects treated for two years with orlistat. J. Am. Med. Assoc. (1999) 281:234-242.
5. FLIER JS, MARATOS-FLIER E: Obesity and the hypothalamus: Novel peptides for new pathways. Cell (1998) 92:437-440. (Pubitemid 28101107)
6. BOUCHARD C, TREMBLAY A, NADEAU A et al.: Genetic effect in resting and exercise metabolic rates. Metabolism (1989) 38:364-370. (Pubitemid 19105724)
7. SCHUTZ Y: Macronutrients and energy balance in obesity. Metabolism (1995) 44:7-11.
8. WEYER C, GAUTIER JF, DANFORTH E: Development of b3-adrenorecptor agonists for the treatment of obesity and diabetes-an update. Diabetes Metab. (1999) 25:11-21. (Pubitemid 29198221)
9. BEAVO JA: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev. (1995) 75:725-748.
10. SODERLING SH, BAYUGA SJ, BEAVO JA: Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. Natl. Acad. Sci. USA (1998) 95:8991-8996. (Pubitemid 28350602)
11. SODERLING SH, BAYUGA SJ, BEAVO JA: Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem. (1998) 273:15553-15558. (Pubitemid 28298167)
12. FISHER DA, SMITH JF, PILLAR JS, DENIS SH, CHENG JB: Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. (1998) 273:15559-15564. (Pubitemid 28298168)
13. LOUGHNEY K, SNYDER PB, UHER L, ROSMAN GJ, FERGUSON K, FLORIO VA: Isolation and characterization of PDE10A, a novel human 3',5'-cyclic nucleotide phosphodiesterase. Gene (1999) 234:109-117. (Pubitemid 29294097)
14. SODERLING SH, BAYUGA SJ, BEAVO JA: Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. USA (1999) 96:7071-7076. (Pubitemid 29275011)
15. FUJISHIGE K, KOTERA J, MICHIBATA H et al.: Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem. (1999) 274:18438-18445.
16. LOUGHNEY K, FERGUSON K: Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods. In: Phosphodiesterase Inhibitors. Schudt C, Dent G, Rabe KF (Eds.) Academic Press, San Diego, USA (1996):1-19.
17. MANGANIELLO VC, SMITH CJ, DEGERMAN E, BELFRAGE P: Cyclic GMP-inhibited cyclic nucleotide phosphodiesterases. Mol. Pharmacol. Cell Regul. (1990) 2:87-116.
18. DEGERMAN E, BELFRAGE P, MANGANIELLO VC: Structure, localization and regulation of cGMP-inhibited phosphodiesterase (PDE3). J. Biol. Chem. (1997) 272:6823-6826. (Pubitemid 27166373)
19. MAURICE DH, HASLAM RJ: Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol. (1990) 37:671-681. (Pubitemid 20171502)
20. MEACCI E, TAIRA M, MOOS M et al.: Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc. Natl. Acad. Sci. USA (1992) 89:3721-3725.
21. TAIRA M, HOCKMAN SC, CALVO JC, TAIRA M, BELFRAGE P, MANGANIELLO VC: Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J. Biol. Chem. (1993) 268: 18573-18579. (Pubitemid 23273792)
22. REINHARDT RR, CHIN E, ZHOU J et al.: Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J. Clin Invest. (1995) 95:1528-1538.
23. LIU H, MAURICE DH: Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: Differential subcellular localization and regulated expression by cAMP. Brit. J. Pharmacol. (1998) 125:1501-1510. (Pubitemid 28548563)
24. LÖBBERT RW, WINTERPACHT A, SEIPEL B, ZABEL BU: Molecular cloning and chromosomal assignment of the human homologue of the rat cGMP-inhibited phosphodiesterase 1 (PDE3A)-a gene involved in fat metabolism located at 11p15.1. Genomcis (1996) 37:211-218. (Pubitemid 26360894)
25. MIKI T, TAIRA M, HOCKMAN S et al.: Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cyclic GMP-inhibited cyclic nucleotide phosphodiesterase family. Genomics (1996) 36:476-485. (Pubitemid 26321970)
26. DEGERMAN E, BELFRAGE P, NEWMAN AH, RICE KC, MANGANIELLO VC: Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J. Biol. Chem. (1987) 262:5797-5807. (Pubitemid 17104167)
27. DEGERMAN E, MANGANIELLO VC, NEWMAN AH, RICE KC, BELFRAGE P: Purification, properties and polyclonal antibodies for the particulate, lowKmcAMP phosphodiesterase from bovine adipose tissue. Second Messengers Phosphoproteins (1988) 12:171-182. (Pubitemid 19265941)
28. ELKS ML, MANGANIELLO VC: Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism and lipolysis in 3T3-L1 adipocytes. Endocrinology (1984) 115:1262-1268. (Pubitemid 14000283)
29. SCHMITZ-PEIFFER C, REEVES ML, DENTON RM: Characterization of the cyclic nucleotide phosphodiesterase isoenzymes present in rat epididymal fat cells. Cell. Signal. (1992) 4:37-49.
30. WIJKANDER J, LANDSTRÖM TR, MANGANIELLO V, BELFRAGE P, DEGERMAN E: Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: Possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology (1998) 139:219-227. (Pubitemid 28166313)
31. KITAMURA T, KITAMURA Y, KURODA S et al.: Insulininduced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serinethreonine kinase Akt. Molec. Cell. Biol. (1999) 19:6286-6296. (Pubitemid 29399333)
32. DORIGO P, GAION RM, MAZZETTO S, MARCOMINI A, MARAGNO I: Amrinone potentiates catecholamineinduced lipolysis in fat cells. Biochem. Pharmacol. (1989) 38:855-858. (Pubitemid 19072690)
33. SHECHTER Y: Differential effects of two phosphodiesterase inhibitors on fat cell metabolism. Endocrinology (1984) 115:1787-1791. (Pubitemid 15206595)
34. LEROY M-J, DEGERMAN E, TAIRA M et al.: Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry (1996) 35:10194-10202. (Pubitemid 26269937)
35. KATHER H, SCHEURER A: Effects of different phosphodiesterase inhibitors on the antilipolytic action of insulin in human adipocytes. Horm. Metabol. Res. (1987) 19:379-381. (Pubitemid 17136245)
36. WILMSHURST PT, THOMPSON DS, JUUL SM, JENKINS BS, COLTART DJ, WEBB-PEPLOE MM: Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. Br. Heart J. (1984) 52:38-48. (Pubitemid 14089495)
37. RUTTIMANN Y, CHIOLÉRO R, REVELLY JP, JEANPRÊTRE N, SCHUTZ Y: Thermogenic effect of amrinone in healthy men. Crit. Care Med. (1994) 22:1235-1240. (Pubitemid 24244829)
38. ARNER P, HELLMÉR J, HAGSTRÖM-TOFT E, BOLINDER J: Effect of phosphodiesterase inhibition with amrinone or theophylline on lipolysis and blood flow in human adipose tissue in vivo as measured with microdialysis. J. Lipid Res. (1993) 34:1737-1743. (Pubitemid 23298717)
39. CHOI OH, SHAMIM MT, PADGETT WL, DALY JW: Caffeine and theophylline analogues: Correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. Life Sci. (1988) 43:387-398.
40. PARSONS WJ, RAMKUMAR V, STILES GL: The new cardiotonic agent sulmazole is an A1 adenosine receptor antagonist and functionally blocks the inhibitory regulator, Gi. Molec. Pharmacol. (1988) 33:441-448.
41. HAGSTÖM-TOFT E, BOLINDER J, ERIKSSON S, ARNER P: Role of phosphodiesterase III in the antilipolytic effect of insulin in vivo. Diabetes (1995) 44:1170-1175.
42. MOBERG E, ENOKSSON S, HAGSTRÖM-TOFT E: Importance of phosphodiesterase 3 for the lipolytic response in adipose tissue during insulin-induced hypoglycemia in normal man. Horm. Metab. Res. (1998) 30:684-688. (Pubitemid 29004014)
43. SCHRAUWEN P, WALDER K, RAVUSSIN E: Human uncoupling proteins and obesity. Obes. Res. (1999) 7:97-105. (Pubitemid 129710567)
44. MAO W, YU XX, ZHONG A et al.: UCP4, a novel brainspecific mitochondrial protein that reduces membrane potential in mammalian cells. FEBS Lett (1999) 443:326-330. (Pubitemid 29080820)
45. NAGASE I, YOSHIDA T, KUNAMOTO K, UMEKAWA T, SAKANE N, NIKAMI H: Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic b3-adrenergic agonist. J. Clin. Invest. (1996) 97:2898-2904. (Pubitemid 26197105)
46. SAVONTAUS E, ROURU J, BOSS O, HUUPPONEN R, KOULU M: Differential regulation of uncoupling proteins by chronic treatments with b3-adrenergic agonist BRL 35135 and metformin in obese fa/fa Zucker rats. Biochem. Biophys. Res. Commun. (1998) 246:899-904. (Pubitemid 28420955)
47. YOSHIDA T, UMEKAWA T, KUMAMOTO K et al.: b3-adrenergic agonist induces a functionally active uncoupling protein in fast and slow-twitch muscle fibers. Am. J. Physiol. (1998) 274:E469-E475.
48. GONG D-W, HE Y, KARAS M, REITMAN M: Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, b3-adrenergic agonists and leptin. J. Biol. Chem. (1997) 272:24129-24132. (Pubitemid 27418606)
49. GHORBANI M, CLAUS TH, HIMMS-HAGEN J : Hypertrophy of brown adipocytes in brown and white adipose tissues and reversal of diet-induced obesity in rats treated with a b3-adrenoreceptor agonist. Biochem. Pharmacol. (1997) 54:121-131. (Pubitemid 27353229)
50. FISHER MH, AMEND AM, BACH TJ et al.: A selective human b3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. J. Clin. Invest. (1998) 101:2387-2393. (Pubitemid 28270433)
51. WEYER C, TATARANNI A, SNITKER S, DANFORTH E, RAVUSSIN E: Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective b3-adrenoreceptor agonist in humans. Diabetes (1998) 47:1555-1561. (Pubitemid 28445342)
52. SCHUIT RC: Factors determining the glucose sensitivity and glucose responsiveness of pancreatic beta cells. Horm. Res. (1996) 46:99-106.
53. SHAFIEE-NICK R, PYNE NJ, FURMAN BL: Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity. Br. J. Pharmacol. (1995) 115:1486-1492.
54. PARKER JC, VANVOLKENBURG MA, KETCHUM RJ, BRAYMAN KL, ANDREWS KM: Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: Contributions of types III and IV to the modulation of insulin secretion. Biochem. Biophys. Res. Commun. (1995) 217:616-923.
55. ZHAO AZ, ZHAO H, TEAGUE J, FUJIMOTE W, BEAVO JA: Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc. Natl. Acad. Sci. USA (1997) 94:3223-3228. (Pubitemid 27157292)
56. FEHNMANN H-C, HERING B-J, WOLF M-J et al.: The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas (1995) 11:196-200.
57. ZHAO AZ, BORNFELDT KE, BEAVO JA: Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J. Clin. Invest. (1998) 102:869-873. (Pubitemid 28419231)
58. EL-METWALLY M, SHAFIEE-NICK R, PYNE NJ, FURMAN BL: The effect of selective phosphodiesterase inhibitors on plasma insulin concentrations and insulin secretion in vitro in the rat. Eur. J. Pharmacol. (1997) 324:227-232. (Pubitemid 27174611)
59. PARKER JC, VANVOLKENBURG MA, NARDONE NA, HARGROVE DM, ANDREWS KM: Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III. Biochem. Biophys. Res. Commun. (1997) 236:665-669. (Pubitemid 27384686)
60. HOUSLAY MK, KILGOUR E: Cyclic nucleotide phosphodiesterases in liver: A review of their characterization, regulation by insulin and glucagon and their role in controlling intracellular cAMP concentrations. Mol. Pharmacol. Cell Regul. (1990) 2:185-224.
61. WATANABE J, SAKO Y, UMEDA F, NAWATA H: Effects of cilostazol, a phosphodiesterase inhibitor, on urinary excretion of albumin and prostaglandins in non-insulin-dependent diabetic patients. Diabetes Res. Clin. Practice (1993) 22:53-59. (Pubitemid 24040563)
62. BODEN G: Fatty acids and insulin resistance. Diabetes Care (1996) 19:394-395. (Pubitemid 26115469)
63. LIU X, PÉRUSSE F, BUKOWIECKI LJ: Mechanism of the antidiabetic effects of the b3-adrenergic agonist CL-316243 in obese Zucker-ZDF rats. Am. J. Physiol. (1998) 274:R1212-R1219.
64. NAKAYA Y, MINAMI A, SAKAMOTO S et al.: Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous NIDDM. Diabetes Obesity Metabol. (1999) 1:37-41.
65. ARNOLD JMO: The role of phosphodiesterase inhibitors in heart failure. Pharmac. Ther. (1993) 57:161-170. (Pubitemid 23175379)
66. CRUICKSHANK JM: Phosphodiesterase III inhibitors: Long-term risks and short-term benefits. Cardiovasc. Drugs Ther. (1993) 7:655-660. (Pubitemid 23309342)
67. KIMURA Y: Selective Type III phosphodiesterase inhibitor as an antithrombotic agent. Nippon Yakurigaku Zasshi (1995) 106:205-16.
68. SHAHID M, VAN AMSTERDAM RGM, DE BOER J, TEN BERGE RE, NICHOLSON CD, ZAAGSMA J: The presence of five cyclic nucleotide phosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effects of selective inhibitors. Br. J. Pharmacol. (1991) 104:471-477.